dc.contributor.author | Ferdinandusse, S, SF | |
dc.contributor.author | Falkenberg, K, KF | |
dc.contributor.author | Koster, J, JK | |
dc.contributor.author | Mooyer, PM | |
dc.contributor.author | Jones, R, RJ | |
dc.contributor.author | van Roermund, C, C | |
dc.contributor.author | Pizzino, A, AP | |
dc.contributor.author | Schrader, M | |
dc.contributor.author | Wanders, R, RW | |
dc.contributor.author | Vanderver, A, AV | |
dc.contributor.author | Waterham, H, HW | |
dc.date.accessioned | 2016-10-12T08:20:50Z | |
dc.date.issued | 2016-10-31 | |
dc.description.abstract | Background
Acyl-CoA binding domain containing protein 5 (ACBD5) is a peroxisomal membrane protein with a
cytosolic acyl-CoA binding domain. Because of its acyl-CoA binding domain, ACBD5 has been
assumed to function as an intracellular carrier of acyl-CoA esters. In addition, a role for ACBD5 in
pexophagy has been suggested. However, the precise role of ACBD5 in peroxisomal metabolism
and/or functioning has not yet been established. Previously, a genetic ACBD5 deficiency was
identified in three siblings with retinal dystrophy and white matter disease. We identified a pathogenic
mutation in ACBD5 in another patient and studied the consequences of the ACBD5 defect in patient
material and in ACBD5-deficient HeLa cells to uncover this role.
Methods
We studied a girl who presented with progressive leukodystrophy, syndromic cleft palate, ataxia and
retinal dystrophy. We performed biochemical, cell biological and molecular studies in patient material
and in ACBD5-deficient HeLa cells generated by CRISPR-Cas9 genome editing.
Results
We identified a homozygous deleterious indel mutation in ACBD5, leading to complete loss of ACBD5
protein in the patient. Our studies showed that ACBD5 deficiency leads to accumulation of very longchain
fatty acids (VLCFAs) due to impaired peroxisomal beta-oxidation. No effect on pexophagy was
found.
Conclusions
Our investigations strongly suggest that ACBD5 plays an important role in sequestering C26-CoA in
the cytosol and thereby facilitates transport into the peroxisome and subsequent beta-oxidation.
Accordingly, ACBD5 deficiency is a novel single peroxisomal enzyme deficiency caused by impaired
VLCFA metabolism and leading to retinal dystrophy and white matter disease. | en_GB |
dc.description.sponsorship | Supported in part by funding through the Marie Curie Initial Training Networks (ITN) action to
KDF, MS and HRW (FP7-2012-PERFUME-316723). MS is supported by the Biotechnology and
Biological Sciences Research Council (BB/K006231/1; BB/N01541X/1). | en_GB |
dc.identifier.citation | Published Online First 31 October 2016 | en_GB |
dc.identifier.doi | 10.1136/jmedgenet-2016-104132 | |
dc.identifier.uri | http://hdl.handle.net/10871/23869 | |
dc.language.iso | en | en_GB |
dc.publisher | BMJ Publishing Group | en_GB |
dc.rights | This is the author accepted manuscript. The final version is available from BMJ Publishing Group via the DOI in this record. | |
dc.subject | Peroxisomal disorder | en_GB |
dc.subject | peroxisomal beta-oxidation | en_GB |
dc.subject | pexophagy | en_GB |
dc.subject | very long-chain fatty acids | en_GB |
dc.subject | acyl-CoA binding domain containing protein 5 | en_GB |
dc.subject | peroxisomal single enzyme deficiency | en_GB |
dc.title | ACBD5 deficiency causes a defect in peroxisomal very long-chain fatty acid metabolism | en_GB |
dc.type | Article | en_GB |
dc.identifier.issn | 0306-6800 | |
dc.identifier.journal | Journal of Medical Ethics | en_GB |